MEMPHASYS LTD (IG7) - Net Assets
Based on the latest financial reports, MEMPHASYS LTD (IG7) has net assets worth €6.84 Million EUR (≈ $7.99 Million USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.43 Million ≈ $14.53 Million USD) and total liabilities (€5.59 Million ≈ $6.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of MEMPHASYS LTD for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.84 Million |
| % of Total Assets | 55.01% |
| Annual Growth Rate | -7.38% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3.16 |
MEMPHASYS LTD - Net Assets Trend (2021–2024)
This chart illustrates how MEMPHASYS LTD's net assets have evolved over time, based on quarterly financial data. Also explore MEMPHASYS LTD balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for MEMPHASYS LTD (2021–2024)
The table below shows the annual net assets of MEMPHASYS LTD from 2021 to 2024. For live valuation and market cap data, see market value of MEMPHASYS LTD.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €6.84 Million ≈ $7.99 Million |
-7.41% |
| 2023-06-30 | €7.38 Million ≈ $8.63 Million |
-3.42% |
| 2022-06-30 | €7.65 Million ≈ $8.94 Million |
-11.16% |
| 2021-06-30 | €8.61 Million ≈ $10.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MEMPHASYS LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 926266300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €57.27 Million | 837.52% |
| Total Equity | €6.84 Million | 100.00% |
MEMPHASYS LTD Competitors by Market Cap
The table below lists competitors of MEMPHASYS LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Brüder Mannesmann Aktiengesellschaft
F:BMM
|
$4.28 Million |
|
Quest PharmaTech Inc
V:QPT
|
$4.28 Million |
|
Traka Resources Ltd
AU:TKL
|
$4.28 Million |
|
KWANGJIN WINTEC CO. Ltd
KQ:090150
|
$4.29 Million |
|
Grand Foundry Limited
NSE:GFSTEELS
|
$4.27 Million |
|
Ecora Resources PLC
LSE:ECOR
|
$4.27 Million |
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
$4.26 Million |
|
NCL International Logistics Public Company Limited
BK:NCL
|
$4.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MEMPHASYS LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,384,689 to 6,837,755, a change of -546,934 (-7.4%).
- Net loss of 4,442,021 reduced equity.
- Share repurchases of 367,974 reduced equity.
- New share issuances of 3,721,001 increased equity.
- Other factors increased equity by 542,060.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.44 Million | -64.96% |
| Share Repurchases | €367.97K | -5.38% |
| Share Issuances | €3.72 Million | +54.42% |
| Other Changes | €542.06K | +7.93% |
| Total Change | €- | -7.41% |
Book Value vs Market Value Analysis
This analysis compares MEMPHASYS LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.30x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.14x to 0.30x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | €0.01 | €0.00 | x |
| 2022-06-30 | €0.01 | €0.00 | x |
| 2023-06-30 | €0.01 | €0.00 | x |
| 2024-06-30 | €0.00 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MEMPHASYS LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -64.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7403.37%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.82x
- Recent ROE (-64.96%) is below the historical average (-38.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -17.27% | 0.00% | 0.00x | 1.69x | €-2.35 Million |
| 2022 | -27.23% | -7668.94% | 0.00x | 1.85x | €-2.85 Million |
| 2023 | -46.08% | -22136.61% | 0.00x | 1.99x | €-4.14 Million |
| 2024 | -64.96% | -7403.37% | 0.00x | 1.82x | €-5.13 Million |
Industry Comparison
This section compares MEMPHASYS LTD's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $50,446,059,214
- Average return on equity (ROE) among peers: -24.61%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MEMPHASYS LTD (IG7) | €6.84 Million | -17.27% | 0.82x | $4.27 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.50 Billion | 7.19% | 0.43x | $138.66K |
| BIORETEC OY (0TN) | $9.74 Million | -47.38% | 0.18x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $464.53 Billion | 11.55% | 0.43x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $554.62 Million | 29.12% | 0.16x | $711.77 Million |
| HeraMED Limited (1I4) | $6.15 Million | -86.78% | 0.27x | $28.30 Million |
| Medtronic PLC (2M6) | $15.97 Billion | 19.39% | 0.91x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $3.02 Billion | -19.02% | 0.05x | $401.71 Million |
| AVITA Medical Inc (51KB) | $72.40 Million | -58.05% | 0.14x | $172.49 Million |
| BRAINCOOL AB (5YL) | $45.23 Million | -85.67% | 1.20x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.75 Billion | -16.50% | 0.09x | $107.57 Million |
About MEMPHASYS LTD
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more